Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the metrics that really move Joint Corp鈥攃linic count growth, franchise royalties, or membership churn? This page brings every SEC disclosure together so you can stop hunting and start understanding. Whether you need the Joint Corp insider trading Form 4 transactions or the latest Joint Corp quarterly earnings report 10-Q filing, Stock Titan delivers them the moment they hit EDGAR.
Our AI engine reads each document line-by-line and serves plain-English answers. Think of it as "Joint Corp SEC filings explained simply"鈥攆rom a 300-page 10-K to a one-page 8-K. Click any filing type below and you鈥檒l see auto-generated key points, ratio calculations, and trend charts:
- Joint Corp annual report 10-K simplified鈥攆ranchise economics, clinic openings, risk factors
- Joint Corp Form 4 insider transactions real-time鈥攁lerts on executive buys and sells
- Joint Corp proxy statement executive compensation鈥攂onus targets tied to same-store sales
- Joint Corp 8-K material events explained鈥攏ew market entries or leadership updates
Need deeper context? Our "understanding Joint Corp SEC documents with AI" module cross-links sections so you can compare revenue per clinic across multiple quarters. For quick takeaways, the "Joint Corp earnings report filing analysis" highlights margin shifts and patient visit growth. Professionals monitoring Joint Corp executive stock transactions Form 4 can set real-time alerts to spot patterns before the market reacts.
Every document, every detail, always current鈥攂ecause informed decisions start with complete, clear data.
The Joint Corp. (JYNT) filed an Item 4.02 8-K stating investors should no longer rely on its FY-24 Form 10-K and Q1-25 Form 10-Q due to misapplied GAAP impairment guidance on clinics classified as held-for-sale. Management, the Audit Committee and auditor BDO agreed the financials contain material errors and will be restated and re-issued.
Preliminary corrections will decrease FY-24 net loss by 鈮� $2.2 million and increase Q1-25 net income by 鈮� $0.5 million; the carrying value of assets held-for-sale rises cumulatively by 鈮� $2.7 million. Critically, the adjustment has no impact on Adjusted EBITDA, cash, cash equivalents or restricted cash.
The company expects to disclose a material weakness in internal control over financial reporting and that prior disclosure controls were ineffective. Amended 10-K/A and 10-Q/A will be filed 鈥渁s soon as practicable.鈥�
Nvidia Corp. (NVDA) 鈥� Form 144 filing reports a proposed sale of 75,000 common shares on 23 Jul 2025 through Charles Schwab, with an aggregate market value of $12.7 million. The seller, identified in related tables as Jen-Hsun Huang, intends to dispose of stock previously acquired via option exercises on 08 Sep 2023 (68,705 sh) and 15 Sep 2023 (6,295 sh), both paid in cash.
The filing details an extensive selling program: 22 separate transactions over the prior three months totaling 1,575,000 shares and roughly $194 million in gross proceeds, with daily blocks ranging from 50,000鈥�75,000 shares between 20 Jun and 22 Jul 2025.
The notice affirms the insider is unaware of undisclosed adverse information, satisfying Rule 144 representations. While Form 144 merely signals intent, the sustained, sizable disposals by the long-time executive could be interpreted as a bearish sentiment or personal diversification move and warrants investor attention.
Schedule 13G filing overview 鈥� The Joint Corp. (JYNT)
On 10 July 2025, Skylands Capital, LLC, a Wisconsin-based investment adviser, submitted a Schedule 13G reporting its beneficial ownership in The Joint Corp. common stock. The filing relates to an event dated 30 June 2025.
- Shares owned: 779,295
- % of outstanding class: 5.1%
- Voting power: Sole power to vote and dispose of all reported shares; no shared power
- Filing basis: Rule 13d-1(b) 鈥� passive investment by an investment adviser (IA)
- Intent statement: Securities acquired and held in the ordinary course, not for the purpose of influencing control
The disclosure means Skylands has crossed the 5 % reporting threshold, giving investors fresh insight into institutional ownership dynamics at The Joint Corp. No other entities or group relationships are identified, and there are no indications of activist intent.
FIGX Capital Acquisition Corp. (Nasdaq: FIGXU) filed an 8-K to report the completion of its initial public offering on 30 June 2025.
- IPO size: 15,065,000 units priced at $10.00 each, including full exercise of the 1,965,000-unit over-allotment option.
- Gross proceeds: $150,165,000.
- Unit structure: each unit contains 1 Class A ordinary share (par value $0.0001) and one-half of one redeemable warrant; a whole warrant is exercisable at $11.50 per share.
- Private placement: 443,470 units sold concurrently for $4,434,700鈥�312,470 units to the sponsor and 131,000 units to Cantor Fitzgerald.
- Trust account funding: the full $150,165,000 (including a deferred underwriting discount of $6,419,000) was placed in a U.S. trust managed by Continental Stock Transfer & Trust.
- An audited balance sheet dated 30 June 2025 is provided as Exhibit 99.1.
The filing confirms FIGX鈥檚 transition to a fully funded special-purpose acquisition company (SPAC); the next milestone will be identifying a business combination within the typical 24-month timeframe.
Joint (NASDAQ:JYNT) agreed to sell the assets of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $11.07 million, with closing targeted on or before 30 Jun 2025 and customary conditions attached. In return, the company will obtain regional developer rights covering 46 existing franchised clinics and 30 future development sites across Northern California, Utah, Nevada, Washington and Oregon, enlarging its franchise pipeline.
In a separate transaction, the company divested five clinics in Kansas and Missouri to 93 Chiro, LLC. Management positions both deals as part of a strategic shift toward an asset-light, royalty-driven model that increases liquidity, cuts operating costs and accelerates unit growth.
FAQ
What is the current stock price of Joint (JYNT)?
What is the market cap of Joint (JYNT)?
What is Joint Corp's core business model?
How does Joint Corp make chiropractic care accessible?
What services do Joint Corp clinics offer?
How does the franchising model contribute to Joint Corp鈥檚 growth?
What distinguishes Joint Corp from its competitors?
How is quality patient care ensured at Joint Corp?
What are the primary operational segments of Joint Corp?
How does Joint Corp integrate innovation into its operations?
